NCPA unveils newly named exec slate
ALEXANDRIA, Va. The National Community Pharmacists Association Tuesday unveiled its complete list of newly installed officers and executive committee members for 2010-2011. All are practicing pharmacists who will serve one-year terms.
The independent pharmacy group tapped the new slate of leaders at its 112th Annual Convention and Trade Exposition, held Oct. 23 to 27 in Philadelphia.
The conference marked the beginning of Robert Greenwood’s term as NCPA president. Greenwood began his pharmacy career in Waterloo, Iowa, where he purchased Hurdle Drug in 1987. He bought a second pharmacy in Denver, Iowa, in 2000, and two years later opened the Professional Compounding Center of Iowa, also in Waterloo. He is a member of the Waterloo City Council and is a graduate of Creighton University School of Pharmacy in Omaha, Neb.
“We are excited to have Bob Greenwood as NCPA’s president,” said Kathleen Jaeger, NCPA EVP and CEO. “He has been a powerful advocate for independent community pharmacies in Iowa and at the national level for years.”
Greenwood called for renewed alliances between pharmacy interest groups, and for advances in pharmacist-delivered patient care models. “By working collectively, we can ensure a brighter future in which independent community pharmacies are indispensable to our healthcare system, creating better outcomes and reducing overall costs for patients,” he said. “In particular, I will work to elevate the understanding, utilization and practice of medication therapy management and patient adherence, to make both a core competency of community pharmacists.”
One new officer was inducted at the 112th NCPA House of Delegates. Named fifth VP was Jeff Carson, owner of four-store Oakdell Pharmacy in San Antonio. The company was founded by Carson’s father John, who served as NCPA president from 2000 to 2001.
Among the other new officers are NCPA president-elect Lonny Wilson of Oklahoma City; Donnie Calhoun of Anniston, Ala., named chair of the executive committee; and new secretary-treasurer David Smith of Brookville, Pa.
The 113th NCPA Annual Convention and Trade Exposition is set for Oct. 8 to 12, 2011, at the Gaylord Opryland Resort & Convention Center in Nashville, Tenn.
CVS/pharmacy, Warner Home Video support the Cystic Fibrosis Foundation
BETHESDA, Md. The Cystic Fibrosis Foundation announced on Monday that it will partner with CVS/pharmacy and Warner Home Video for the second year to raise funds for cystic fibrosis through the sale of classic family movies this holiday season.
From now through Dec. 28, CVS/pharmacy will sell four animated holiday movies from Warner Home Video, including “How the Grinch Stole Christmas,” “The Year Without a Santa Claus,” “Charlie Brown’s Christmas Tales” and “The Polar Express.” The videos will be sold exclusively at CVS/pharmacy. For every video purchased, CVS/pharmacy and Warner Home Video will donate $5 to benefit the Foundation.
Cystic fibrosis is a fatal genetic disease that causes life-threatening lung infections and premature death. It affects about 70,000 people worldwide. The foundation has fueled dramatic improvements in research and care that have changed the prognosis for people with the disease. Where most children with cystic fibrosis once died before reaching elementary school, now people with the disease live into their 30s and beyond.
RA patients may benefit from weekly injection of Orencia, study finds
NEW YORK Patients with rheumatoid arthritis derive about as much benefit from a weekly injection of a biotech drug made by Bristol-Myers Squibb for the disease as they do from receiving it via IV on a monthly basis, according to late-stage clinical trial data released Monday.
Bristol announced results of a phase-3 study showing that patients with moderate to severe RA receiving a weekly injection under the skin of Orencia (abatacept) showed similar improvements to those receiving the IV. Results of the study will be presented this week at the American College of Rheumatology’s annual scientific meeting in Atlanta.
The study included 1,457 patients who had moderate to severe RA and did not respond adequately to the drug methotrexate. Patients were placed at random in groups that received either weekly injections of Orencia with a single IV loading dose or IV Orencia with methotrexate. After six months, 69.8% of those receiving injections and 65% of those on IV were showing improvements.
“These findings are significant because they demonstrate that subcutaneous Orencia may provide an additional administration option for patients and physicians,” lead study author and Stanford University medical professor Mark Genovese said. “It is important for patients and physicians to have treatment options when managing RA.”